Published in Anat Rec A Discov Mol Cell Evol Biol on October 01, 2004
Congenital heart block: identification of autoantibody binding site on the extracellular loop (domain I, S5-S6) of alpha(1D) L-type Ca channel. J Autoimmun (2009) 1.06
Fetal ECG: a novel predictor of atrioventricular block in anti-Ro positive pregnancies. Heart (2006) 1.02
Antibodies to amino acid 200-239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block. Clin Exp Immunol (2008) 0.97
52-kDa Ro/SSA epitopes preferentially recognized by antibodies from mothers of children with neonatal lupus and congenital heart block. Arthritis Res Ther (2006) 0.84
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum (2012) 6.85
Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med (2005) 5.50
Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med (2015) 3.63
The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2006) 3.05
Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation (2008) 2.54
Myocardial-tissue-specific phenotype of maternal microchimerism in neonatal lupus congenital heart block. Lancet (2003) 2.13
Sex ratios among children of lupus pregnancies. Arthritis Rheum (2013) 1.98
Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. J Clin Invest (2006) 1.76
Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. Arthritis Rheum (2004) 1.76
Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost (2005) 1.73
Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation (2011) 1.68
Genetic association of cutaneous neonatal lupus with HLA class II and tumor necrosis factor alpha: implications for pathogenesis. Arthritis Rheum (2004) 1.67
Shedding of endothelial protein C receptor contributes to vasculopathy and renal injury in lupus: in vivo and in vitro evidence. Kidney Int (2005) 1.66
Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. Arthritis Rheum (2008) 1.65
Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum (2010) 1.52
A central role of plasmin in cardiac injury initiated by fetal exposure to maternal anti-Ro autoantibodies. Rheumatology (Oxford) (2013) 1.41
Epidemiology, etiology, detection, and treatment of autoantibody-associated congenital heart block in neonatal lupus. Curr Rheumatol Rep (2007) 1.36
Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum (2009) 1.32
Maternal antibody responses to the 52-kd SSA/RO p200 peptide and the development of fetal conduction defects. Arthritis Rheum (2005) 1.27
Ro60-associated single-stranded RNA links inflammation with fetal cardiac fibrosis via ligation of TLRs: a novel pathway to autoimmune-associated heart block. J Immunol (2010) 1.26
Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation (2012) 1.20
Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis (2010) 1.19
Transdifferentiation of cardiac fibroblasts, a fetal factor in anti-SSA/Ro-SSB/La antibody-mediated congenital heart block. J Immunol (2002) 1.18
Cytokine polymorphisms and histologic expression in autopsy studies: contribution of TNF-alpha and TGF-beta 1 to the pathogenesis of autoimmune-associated congenital heart block. J Immunol (2003) 1.17
Identification of candidate loci at 6p21 and 21q22 in a genome-wide association study of cardiac manifestations of neonatal lupus. Arthritis Rheum (2010) 1.13
Neonatal lupus syndromes. Rheum Dis Clin North Am (2007) 1.11
Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol (2009) 1.10
Congenital heart block: identification of autoantibody binding site on the extracellular loop (domain I, S5-S6) of alpha(1D) L-type Ca channel. J Autoimmun (2009) 1.06
Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis Rheum (2010) 1.06
Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus. Rheumatology (Oxford) (2012) 1.06
A novel role of endothelin-1 in linking Toll-like receptor 7-mediated inflammation to fibrosis in congenital heart block. J Biol Chem (2011) 1.03
Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum (2004) 1.01
Ro60 requires Y3 RNA for cell surface exposure and inflammation associated with cardiac manifestations of neonatal lupus. J Immunol (2013) 1.00
Binding of anti-SSA antibodies to apoptotic fetal cardiocytes stimulates urokinase plasminogen activator (uPA)/uPA receptor-dependent activation of TGF-β and potentiates fibrosis. J Immunol (2011) 0.98
Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis Rheum (2012) 0.98
Role of hypoxia and cAMP in the transdifferentiation of human fetal cardiac fibroblasts: implications for progression to scarring in autoimmune-associated congenital heart block. Arthritis Rheum (2007) 0.96
Challenges in bringing the bench to bedside in drug development for SLE. Nat Rev Drug Discov (2004) 0.95
Congenital heart block in neonatal lupus: the pediatric cardiologist's perspective. Indian J Pediatr (2002) 0.94
Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. Arthritis Rheum (2008) 0.94
Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response. Arthritis Rheum (2008) 0.94
Anti-La/SSB antibodies transported across the placenta bind apoptotic cells in fetal organs targeted in neonatal lupus. Arthritis Rheum (2002) 0.94
Subcellular redistribution of la/SSB autoantigen during physiologic apoptosis in the fetal mouse heart and conduction system: a clue to the pathogenesis of congenital heart block. Arthritis Rheum (2002) 0.93
Brief Report: IRF5 systemic lupus erythematosus risk haplotype is associated with asymptomatic serologic autoimmunity and progression to clinical autoimmunity in mothers of children with neonatal lupus. Arthritis Rheum (2012) 0.92
β2-glycoprotein I and protection from anti-SSA/Ro60-associated cardiac manifestations of neonatal lupus. J Immunol (2011) 0.92
The role of biomarkers in the assessment of lupus. Best Pract Res Clin Rheumatol (2005) 0.91
Exposure and binding of selected immunodominant La/SSB epitopes on human apoptotic cells. Arthritis Rheum (2005) 0.90
Birth order, gender and recurrence rate in autoantibody-associated congenital heart block: implications for pathogenesis and family counseling. Lupus (2003) 0.90
Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus. J Rheumatol (2009) 0.89
Autoantibodies against the serotoninergic 5-HT4 receptor and congenital heart block: a reassessment. J Autoimmun (2005) 0.88
Complement receptor 3 influences toll-like receptor 7/8-dependent inflammation: implications for autoimmune diseases characterized by antibody reactivity to ribonucleoproteins. J Biol Chem (2013) 0.88
Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis. Rheumatology (Oxford) (2009) 0.87
Umbilical cord blood levels of maternal antibodies reactive with p200 and full-length Ro 52 in the assessment of risk for cardiac manifestations of neonatal lupus. Arthritis Care Res (Hoboken) (2012) 0.86
Intravenous immunoglobulin and placental transport of anti-Ro/La antibodies: comment on the letter by Kaaja and Julkunen. Arthritis Rheum (2004) 0.85
Rituximab: wanted dead or alive... Arthritis Rheum (2010) 0.84
Anti-La/SSB antiidiotypic antibodies in maternal serum: a marker of low risk for neonatal lupus in an offspring. Arthritis Rheum (2006) 0.84
Clearance of apoptotic cells: TGF-beta in the balance between inflammation and fibrosis. J Leukoc Biol (2003) 0.84
Long-term followup of children with neonatal lupus and their unaffected siblings. Arthritis Rheum (2002) 0.84
Identifying an early marker for congenital heart block: when is a long PR interval too long? Comment on the article by Sonesson et al. Arthritis Rheum (2005) 0.84
Hepatobiliary disease in neonatal lupus: prevalence and clinical characteristics in cases enrolled in a national registry. Pediatrics (2002) 0.84
Cardiac manifestations of neonatal lupus: a review of autoantibody-associated congenital heart block and its impact in an adult population. Cardiol Rev (2012) 0.84
More to death than dying: apoptosis in the pathogenesis of SSA/Ro-SSB/La-associated congenital heart block. Rheum Dis Clin North Am (2004) 0.83
Antibody reactivity to alpha-enolase in mothers of children with congenital heart block. J Rheumatol (2009) 0.82
Estrogens and lupus: bubbling cauldron or another overrated Witches' Brew? Arthritis Rheum (2007) 0.82
Autoimmunity as a result of escape from RNA surveillance. J Immunol (2006) 0.81
Current therapies for lupus nephritis in an ethnically heterogeneous cohort. J Rheumatol (2009) 0.81
Neonatal lupus: advances in understanding pathogenesis and identifying treatments of cardiac disease. Curr Opin Rheumatol (2012) 0.80
Does the cellular localization of antigens in or on apoptotic blebs influence the pathogenicity or benefit of cognate antibodies? Comment on the article by Dieudé et al. Arthritis Rheum (2003) 0.78
The presence of IgG antibodies reactive with components of the SSA/Ro-SSB/La complex in human breast milk: implications in neonatal lupus. Arthritis Rheum (2002) 0.78
Reproductive health in SLE. Best Pract Res Clin Rheumatol (2002) 0.78
Brief report: enrichment of associations in genes with fibrosis, apoptosis, and innate immunity functions with cardiac manifestations of neonatal lupus. Arthritis Rheum (2012) 0.77
Preferential transmission of genetic risk variants of candidate loci at 6p21 from asymptomatic grandparents to mothers of children with neonatal lupus. Arthritis Rheum (2012) 0.77
Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus. Curr Opin Rheumatol (2017) 0.77
Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis. JCI Insight (2017) 0.76
Prevention and treatment in utero of autoimmune-associated congenital heart block. Cardiol Rev (2014) 0.76
Predictors of Pregnancy Outcomes in Patients With Lupus. Ann Intern Med (2016) 0.76
Dispelling the preconceived notion that lupus pregnancies result in poor outcomes. J Rheumatol (2005) 0.76
Hypothyroidism and antithyroglobulin and antithyroperoxidase antibodies in the pathogenesis of autoimmune associated congenital heart block. J Rheumatol (2006) 0.76
Connective tissue diseases: What does the death of Riquent hold for the future of SLE? Nat Rev Rheumatol (2009) 0.75
Dysregulation of the microvasculature in nonlesional non-sun-exposed skin of patients with lupus nephritis. J Rheumatol (2012) 0.75
Finding the "PR-fect" solution: what is the best tool to measure fetal cardiac PR intervals for the detection and possible treatment of early conduction disease? Congenit Heart Dis (2012) 0.75
Congenital heart block: do fetal factors fuel the fire from inflammation to fibrosis? Lupus (2003) 0.75
Doppler fetal mechanical PR interval prolongation with positive maternal anti-RNP but negative SSA/Ro and SSB/La auto-antibodies. Prenat Diagn (2010) 0.75
Reply: To PMID 23044629. Arthritis Rheum (2013) 0.75
Use of hydroxychloroquine in Japan. J Rheumatol (2012) 0.75